Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF

Journal of Clinical Investigation

Volumn 109, Issue 6, 2002, Pages 805-815

  Poulaki, Vassiliki ^a,b   Qin, Wenying ^a,b   Joussen, Antonia M ^a,b,c   Hurlbut, Peter ^a   Wiegand, Stanley J ^d   Rudge, John ^d   Yancopoulos, George D ^d   Adamis, Anthony P ^a,b,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN P42; SYNAPTOPHYSIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; INSULIN TREATMENT; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; RETINA; RISK FACTOR;

EID: 0036196081     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0213776     Document Type: Article

References (53)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Blood glucose concentrations and progression of diabetic retinopathy: The seven year results of the Oslo study
3. Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control
4. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus
5. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control And Complications Trial
6. The effect of longterm intensified insulin treatment on the development of microvascular complications of diabetes mellitus
7. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus
8. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM
9. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
11. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
12. Molecular and biological properties of the vascular endothelial growth factor family of proteins
13. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
14. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
15. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
16. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy
17. Vascular endothelial growth factor plays a role in hyperpermeabiIity of diabetic of diabetic retinal vessels
18. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate
19. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes
20. Insulin action and the insulin signaling network
21. Isolation and expression of cDNAs from rainbow trout (Oncorhynchus mykiss) that encode two novel basic helix-loopHelix/PER-ARNT-SIM (bHLH/PAS) proteins with distinct functions in the presence of the aryl hydrocarbon receptor. Evidence for alternative mRNA splicing and dominant negative activity in the bHLH/PAS family
22. Hypoxia-inducible factor 1 is a basic-helix-loop- helix-PAS heterodimer regulated by cellular 02 tension
23. The hypoxic response: Huffing and HIFing
24. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP
25. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002
26. MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products
27. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin
28. RO 31-8220 and RO 31-7549 show improved selectivity for protein kinase C over staurosporine in macrophages
29. C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo
30. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
31. The binding of T-1824 and structurally related diazo dyes by plasma proteins
32. Sensitive blood-retinal barrier breakdown quantitation using Evans blue
33. VEGF-initiated blood-retinal barrier breakdown in early diabetes
34. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT
35. Effects of intensified insulin treatment on various lesions of diabetic retinopathy
36. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: The Oslo study
37. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulindependent diabetics
38. Influence oflong-term insulin infusion pump treatment of type I diabetes on diabetic retinopathy
39. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: A population study
40. Hypoxiainducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension
41. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit
42. Insulin signalling leading to proliferation, survival and membrane ruffling in C2C12 myoblasts
43. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells
44. Suppression of diabetic retinopathy with angiopoietin-1
45. p42/p44 mitogen-activated protein kinases phosphorylate hypoxiainducible Factor 1alpha HIF-1alpha) and enhance the transcriptional activity of HIF-1
46. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver
47. Induction of vascular endothelial growth factor by hypoxia is modulated by a phospharidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
48. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization
49. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I
50. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways
51. Intravetreous injections of vascuIar endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate
52. Advanced glycation end products increase retinal vascular endothelial growth factor expression
53. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo